FIRST-LINE IBRANCEĀ® (PALBOCICLIB) COMBINATION THERAPY IN HR+, HER2- METASTATIC BREAST CANCER
The Pharma Data
MARCH 25, 2021
These findings represent the first comprehensive comparative effectiveness analysis of survival outcomes for a CDK 4/6 inhibitor in routine clinical practice and were published online in Breast Cancer Research. However, this observational analysis differs from the randomized clinical trial in several ways. 2,3 In the U.S.,
Let's personalize your content